We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$790M
1-Year Est. Return
223.66%
This Fund
S&P 500
This Quarter
Est. Return
-4.67%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$739M
AUM Growth
-$91.7M
(-11%)
Cap. Flow
-$6.12M
Cap. Flow
% of AUM
-0.83%
Top 10 Holdings %
Top 10 Hldgs %
94.94%
Holding
17
New
–
Increased
6
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$783K |
| 2 |
JBIO
Jade Biosciences
JBIO
|
+$515K |
| 3 |
Dianthus Therapeutics
DNTH
|
+$218K |
| 4 |
Dyne Therapeutics
DYN
|
+$207K |
| 5 |
TECX
Tectonic Therapeutic
TECX
|
+$23.8K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$4.08M |
| 2 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
+$3.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kymera Therapeutics
KYMR
$8.25B
| $174M | 23.5% |
5,858,262
-126,474
| -2% | -$4.08M |
|
|
2
Dyne Therapeutics
DYN
$4.71B
| $114M | 15.42% |
9,885,449
+15,966
| +0.2% | +$207K |
|
|
DAWN
3
DELISTED
Day One Biopharmaceuticals
DAWN
| $102M | 13.77% |
7,608,394
+40,077
| +0.5% | +$783K |
|
4
Disc Medicine
IRON
$2.93B
| $73.4M | 9.93% |
3,461,784
| – | – |
|
|
VIGL
5
DELISTED
Vigil Neuroscience
VIGL
| $57.1M | 7.74% |
5,836,874
| – | – |
|
|
THRD
6
DELISTED
Third Harmonic Bio
THRD
| $44.9M | 6.08% |
10,907,859
| – | – |
|
|
JBIO
7
Jade Biosciences
JBIO
$1.17B
| $41.1M | 5.57% |
58,264
+621
| +1% | +$515K |
|
8
Replimune Group
REPL
$1B
| $37.1M | 5.02% |
2,098,300
| – | – |
|
|
GBIO
9
DELISTED
Generation Bio
GBIO
| $35.6M | 4.82% |
827,948
+60
| +0% | +$2.9K |
|
|
AKRO
10
DELISTED
Akero Therapeutics
AKRO
| $22.7M | 3.08% |
594,251
| – | – |
|
|
IMA
11
ImageneBio Inc
IMA
$64.2M
| $17.3M | 2.34% |
418,182
| – | – |
|
12
Xilio Therapeutics
XLO
$59.5M
| $8.75M | 1.18% |
197,096
| – | – |
|
|
TECX
13
Tectonic Therapeutic
TECX
$527M
| $4.54M | 0.61% |
378,448
+1,709
| +0.5% | +$23.8K |
|
|
14
Dianthus Therapeutics
DNTH
$5.8B
| $3.01M | 0.41% |
236,981
+19,697
| +9% | +$218K |
|
15
Viridian Therapeutics
VRDN
$2.13B
| $2.29M | 0.31% |
90,072
| – | – |
|
16
Spero Therapeutics
SPRO
$66.6M
| $1.5M | 0.2% |
1,031,160
| – | – |
|
|
FSTX
17
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| – | – |
-599,524
| Closed | -$3.79M |
|
Similar funds
AWG
AT
MTWSIF
VH
M
AI
VCM
SWIG
Atlas Venture Life Science Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Atlas Venture Life Science Advisors held 17 positions worth $739M, down 11% from $830M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Atlas Venture Life Science Advisors's Q1 2023 filing shows 6 increased, 1 reduced and 1 closed positions. The largest sale was Kymera Therapeutics, an estimated $4.08M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Atlas Venture Life Science Advisors added most to Day One Biopharmaceuticals in Q1 2023, an estimated $783K increase.
- Atlas Venture Life Science Advisors's biggest Q1 2023 reduction was Kymera Therapeutics, cutting an estimated $4.08M.
- Atlas Venture Life Science Advisors fully exited F-star Therapeutics, Inc. Common Stock in Q1 2023, selling an estimated $3.79M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $739M portfolio in Q1 2023.
- Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q1 2023.
- Atlas Venture Life Science Advisors's portfolio value fell 11% quarter-over-quarter to $739M.
Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2023, filed 15 May 2023.